MYD88在弥漫性大B细胞淋巴瘤中的表达及其临床病理意义  

Expression of MYD88 and its significance in diffuse large B-cell lymphoma

作　　者：梁群英[1] 张玉文[1] 贺森[1] LIANG Qun-ying;ZHANG Yu-wen;He Sen(Department of Pathology, First People's Hospital, Henan Shangqiu 476100)

机构地区：[1]商丘市第一人民医院病理科,河南商丘476100

出　　处：《医学检验与临床》2019年第6期19-21,共3页Medical Laboratory Science and Clinics

摘　　要：目的:研究髓样分化因子88 (MYD88)在弥漫性大B细胞淋巴瘤(DLBCL)中的表达,并探讨其与临床预后的关系.方法:采用免疫组化法检测69例DLBCL中MYD88蛋白的表达水平.结果: 69例DLBCL中MYD88蛋白的阳性表达率分别为27.5% (19/69),与患者性别、部位和分期无关(P>0.05);MYD88蛋白在60岁以上的患者表达率39.5% (17/43)高于60岁以下的患者7.6% (2/26) (P<0.025);GCB型阳性患者表达率为8.3% (2/24)明显低于non-GCB型患者37.7% (17/45) (P<0.05);MYD88表达的DLBCL患者的平均生存时间19.7月明显短于无表达的患者(34.8月) (P<0.02).结论: MYD88蛋白表达上调可能是DLBCL发生发展的重要因素,并可能是DLBCL一个新的预后不良因子.Objective: This study aims to investigate the expression of myeloid differentiation factor 88 (MYD88) and its significance in diffuse large B-cell lymphoma. Methods: The expression of MYD88 was detected by immunohistochemistry in 69 patients with diffuse large B-cell lymphomas. Results: The positive rate of MYD88 in cases of DLBCL was 27.5 (17/69) . The expression of MYD88 was not associated with gender, lesion site or stage. The positive rate of MYD88 in patients older than 60years group was higher than that in less than 60years group (P<0.025) .The expression of MYD88 in cases of non-GCB type group 37.7% (17/45) was significantly higher than that of GCB type group 8.3% (2/24) (P<0.05) . Moreover, the mean survival period in DLBCL patients with MYD88 expression was shorter than the MYD88-negative group. Conclusion: The expression of MYD88 may play an important role in the development and progression of DLBCL. Furthermore, the expression of MYD88 might be a new unfavorable prognosis factor of DLBCL.

关 键 词：淋巴瘤 B细胞 预后 髓样分化因子88 

分 类 号：R733.4[医药卫生—肿瘤]